|Day Low/High||2.40 / 2.51|
|52 Wk Low/High||1.41 / 3.67|
Investors in IntelliPharmaCeutics International Inc saw new options begin trading this week, for the July 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors in IntelliPharmaCeutics International Inc saw new options begin trading this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IPCI options chain for the new December 16th contracts and identified one put and one call contract of particular interest.
Intellipharmaceutics (IPCI) and Mallinckrodt (MNK) have reached a license and commercial supply agreement.
The promotion of Paul Campanelli to CEO indicates a change in the company's focus from acquiring other firms to its roots as a generic pharmaceutical firm.
Catalent and West Pharmaceutical Services provide products and services to biotech and pharmaceutical firms. Intellipharmaceutics is a small-cap firm on the rise.